Literature DB >> 29054949

Metachronous solitary plasmacytoma.

Robin Khosa1, Shishir Seth2, Sapna Nangia1.   

Abstract

Solitary plasmacytoma is a rare disorder comprising 5%-10% of all plasma cell neoplasms. Progression to multiple myeloma is the most common pattern of relapse. Appearance of new lesions without any systemic disease is the most unusual pattern of relapse seen in <2% cases. We present a case of a 46-year-old female who presented with features of third and seventh cranial nerve palsy, diagnosed with solitary plasmacytoma, with no evidence of any systemic disease. As per standard recommendations, the patient received radiotherapy to the local site. The patient developed relapse twice, at three sites, during the follow-up period. Investigations revealed no evidence of any systemic disease. In view of repeat relapses, the patient was started on immune modulatory agent. Two and half years after the last radiotherapy, the patient is symptom free with no evidence of any new lesion. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  haematology (incl blood transfusion); oncology; radiotherapy

Mesh:

Substances:

Year:  2017        PMID: 29054949      PMCID: PMC5665239          DOI: 10.1136/bcr-2017-221780

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  24 in total

1.  Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party.

Authors:  Sevil Kilciksiz; Omur Karakoyun Celik; Yucel Pak; Ayse Nur Demiral; Mustafa Pehlivan; Okan Orhan; Fusun Tokatli; Fulya Agaoglu; Burhanedtin Zincircioglu; Beste Melek Atasoy; Naciye Ozseker; Ozlem Yersal; Umar Niang; Ayfer Haydaroglu
Journal:  Am J Hematol       Date:  2008-09       Impact factor: 10.047

2.  Solitary plasmacytoma of the axis vertebra presenting as severe neck pain.

Authors:  Pradip Kumar Sinha; Rudrajit Paul; Ramtanu Bandyopadhyay; Arnab Roy
Journal:  J Assoc Physicians India       Date:  2011-05

3.  Solitary plasmacytoma of bone: Mayo Clinic experience.

Authors:  D A Frassica; F J Frassica; M F Schray; F H Sim; R A Kyle
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-01       Impact factor: 7.038

4.  Solitary plasmacytoma of bone and soft tissue.

Authors:  T W Bolek; R B Marcus; N P Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-09-01       Impact factor: 7.038

Review 5.  Solitary plasmacytoma of bone and asymptomatic multiple myeloma.

Authors:  M A Dimopoulos; L A Moulopoulos; A Maniatis; R Alexanian
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

6.  Solitary plasmacytoma of cervical spine: treatment and prognosis in patients with neurological lesions and spinal instability.

Authors:  Wending Huang; Dong Cao; Junming Ma; Xinghai Yang; Jianru Xiao; Wei Zheng; Dapeng Feng; Zhipeng Wu; Quan Huang; Deyu Chen; Lianshun Jia
Journal:  Spine (Phila Pa 1976)       Date:  2010-04-15       Impact factor: 3.468

7.  Improved outcome in solitary bone plasmacytomata with combined therapy.

Authors:  A Avilés; J Huerta-Guzmán; S Delgado; A Fernández; J C Díaz-Maqueo
Journal:  Hematol Oncol       Date:  1996-09       Impact factor: 5.271

Review 8.  Solitary bone plasmacytoma and extramedullary plasmacytoma.

Authors:  Meletios A Dimopoulos; George Hamilos
Journal:  Curr Treat Options Oncol       Date:  2002-06

9.  Prognostic value of angiogenesis in solitary bone plasmacytoma.

Authors:  Shaji Kumar; Rafael Fonseca; Angela Dispenzieri; Martha Q Lacy; John A Lust; Linda Wellik; Thomas E Witzig; Morie A Gertz; Robert A Kyle; Philip R Greipp; S Vincent Rajkumar
Journal:  Blood       Date:  2002-10-17       Impact factor: 22.113

10.  [Apparently isolated plasmacytoma of bone. Clinical and prognostic data. 114 cases and review of literature (author's transl)].

Authors:  R Bataille; J Sany; H Serre
Journal:  Nouv Presse Med       Date:  1981-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.